nach oben

European Archives of Oto-Rhino-Laryngology

Erschienen in:

18.10.2021 | Head and Neck

HPV status and therapeutic initial strategy impact on survival and oncologic outcomes: 5-year results from the multicentric prospective cohort of oropharyngeal cancers Papillophar

verfasst von: Dorian Culié, Alexandra Rousseau, Jean-Luc Pretet, Jean Lacau Saint Guily

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

After the 2 years of follow-up, we aimed to evaluate at 5 years the impact of human papillomavirus (HPV) status, tobacco, and initial treatment approach on progression-free survival (PFS) and overall survival (OS) of patients with oropharyngeal cancer (OPC) in France.

Methods

Papillophar study was designed as a prospective cohort of 340 OPC patients in 14 French hospitals. HPV-positive status (21.7%) was defined with PCR (positivity for HPV DNA and E6/E7 mRNA). Cox proportional hazard models were used to assess the relationship between PFS, OS, HPV, and other prognostic factors. The combined effect of HPV status with smoking, stage, or initial treatment on PFS was also evaluated.

Results

HPV-pos patients had better PFS than HPV-neg patients (HR = 0.46; 95% CI: 0.29–0.74), and worse for older patients (HR for 5-year age increase = 1.14), UICC stage 4 from the 7th TNM classification compared to stage 1–2 (HR = 2.58; CI: 1.33–5.00), and those having had radiotherapy (HR = 2.07; 95% CI: 1.36–3.16) or induction chemotherapy (HR = 2.11; 95% CI: 1.32–3.38) instead of upfront surgery. HPV-neg patients encountered a larger incidence of loco-regional disease than HPV-pos patients (31.5% and 14.0%, respectively, p = 0.0001). Distant metastases proportion was similar. HPV-neg patients developed more second primary tumor than HPV-pos patients (11.7% vs. 3.3%, p = 0.02).

Conclusions

5-year follow-up confirms the specifically improved prognosis in HPV-positive patients. The prognosis is nevertheless significantly modified through clinical and therapeutical variations.

Nur mit Berechtigung zugänglich

Louie KS, Mehanna H, Sasieni P (2015) Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025. Oral Oncol 51(4):341–348. https://doi.org/10.1016/j.oraloncology.2015.01.002CrossRefPubMed

Chaturvedi AK, Engels EA, Pfeiffer RM et al (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29(32):4294–4301. https://doi.org/10.1200/JCO.2011.36.4596CrossRefPubMedPubMedCentral

Marur S, D’Souza G, Westra WH, Forastiere AA (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11(8):781–789. https://doi.org/10.1016/S1470-2045(10)70017-6CrossRefPubMedPubMedCentral

Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363(1):24–35. https://doi.org/10.1056/NEJMoa0912217CrossRefPubMedPubMedCentral

Benson E, Li R, Eisele D, Fakhry C (2014) The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. Oral Oncol 50(6):565–574. https://doi.org/10.1016/j.oraloncology.2013.09.008CrossRefPubMed

Sedaghat AR, Zhang Z, Begum S et al (2009) Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. Laryngoscope 119(8):1542–1549. https://doi.org/10.1002/lary.20533CrossRefPubMed

Chaturvedi AK, Anderson WF, Lortet-Tieulent J et al (2013) Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 31(36):4550–4559. https://doi.org/10.1200/JCO.2013.50.3870CrossRefPubMedPubMedCentral

Simard EP, Torre LA, Jemal A (2014) International trends in head and neck cancer incidence rates: differences by country, sex and anatomic site. Oral Oncol 50(5):387–403. https://doi.org/10.1016/j.oraloncology.2014.01.016CrossRefPubMed

St Guily JL, Jacquard A-C, Prétet J-L et al (2011) Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France—The EDiTH VI study. J Clin Virol 51(2):100–104. https://doi.org/10.1016/j.jcv.2011.03.003CrossRefPubMed

10.

Chaturvedi AK, D’Souza G, Gillison ML, Katki HA (2016) Burden of HPV-positive oropharynx cancers among ever and never smokers in the US population. Oral Oncol 60:61–67. https://doi.org/10.1016/j.oraloncology.2016.06.006CrossRefPubMed

11.

Burki TK (2016) France announces tobacco legislation plan US legislation has little eff ect on chemotherapy prescribing. Lancet Oncol 15(12):e532. https://doi.org/10.1016/S1470-2045(14)70495-4CrossRef

12.

Chau NG, Rabinowits G, Haddad RI (2014) Human papillomavirus-associated oropharynx cancer (HPV-OPC): treatment options. Curr Treat Options Oncol 15(4):595–610. https://doi.org/10.1007/s11864-014-0309-1CrossRefPubMed

13.

Culié D, Garrel R, Viotti J et al (2018) Impact of HPV-associated p16-expression and other clinical factors on therapeutic decision-making in patients with oropharyngeal cancer: a GETTEC multicentric study. Eur J Surg Oncol 44(12):1908–1913. https://doi.org/10.1016/j.ejso.2018.05.022CrossRefPubMed

14.

Kamran SC, Qureshi MM, Jalisi S, Salama A, Grillone G, Truong MT (2017) Primary surgery-versus primary radiation-based treatment for locally advanced oropharyngeal cancer. Laryngoscope. https://doi.org/10.1002/lary.26903CrossRefPubMed

15.

Roden DF, Schreiber D, Givi B (2017) Triple-modality treatment in patients with advanced stage tonsil cancer. Cancer 123(17):3269–3276. https://doi.org/10.1002/cncr.30728CrossRefPubMed

16.

Gillison ML, Trotti AM, Harris J et al (2019) Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 393(10166):40–50. https://doi.org/10.1016/S0140-6736(18)32779-XCrossRefPubMed

17.

Mehanna H, Robinson M, Hartley A et al (2019) Articles Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 393:51–60. https://doi.org/10.1016/S0140-6736(18)32752-1CrossRefPubMedPubMedCentral

18.

Lacau GJ, Rousseau A, Baujat B et al (2017) Oropharyngeal cancer prognosis by tumour HPV status in France: the multicentric Papillophar study. Oral Oncol 67:29–36. https://doi.org/10.1016/j.oraloncology.2017.01.012CrossRef

19.

Cubie HA, Cuschieri K (2013) Understanding HPV tests and their appropriate applications. Cytopathology 24(5):289–308. https://doi.org/10.1111/cyt.12083CrossRefPubMed

20.

Jung AC, Rickman D, Briolat J et al (2009) Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int J Cancer 126(8):1882–1894. https://doi.org/10.1002/ijc.24911CrossRef

21.

Fakhry C, Zhang Q, Nguyen-Tân F et al (2017) Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer. J Clin Oncol 35:4057–4065. https://doi.org/10.1200/JCOCrossRefPubMedPubMedCentral

22.

Rodrigo JP, Heideman DAM, García-Pedrero JM et al (2014) Time trends in the prevalence of HPV in oropharyngeal squamous cell carcinomas in northern Spain (1990–2009). Int J Cancer 134(2):487–492. https://doi.org/10.1002/ijc.28355CrossRefPubMed

23.

Bozec A, Culie D, Poissonnet G, Dassonville O (2019) Current role of primary surgical treatment in patients with head and neck squamous cell carcinoma. Curr Opin Oncol. https://doi.org/10.1097/CCO.0000000000000531CrossRefPubMed

24.

Kelly JR, Park HS, An Y et al (2017) Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer. Oral Oncol 2018(79):64–70. https://doi.org/10.1016/j.oraloncology.2018.02.017CrossRef

25.

Seikaly H, Biron VL, Zhang H et al (2015) Role of primary surgery in the treatment of advanced oropharyngeal cancer. Head Neck 1:571–579

26.

O’Sullivan B, Huang SH, Su J et al (2016) Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol 17(4):440–451. https://doi.org/10.1016/S1470-2045(15)00560-4CrossRefPubMed

27.

Mirghani H, Lacroix L, Rossoni C et al (2018) Does smoking alter the mutation profile of human papillomavirusedriven head and neck cancers? Eur J Cancer. https://doi.org/10.1016/j.ejca.2018.02.013CrossRefPubMed

28.

Huang SH, Perez-Ordonez B, Weinreb I et al (2013) Natural course of distant metastases following radiotherapy or chemoradiotherapy in HPV-related oropharyngeal cancer. Oral Oncol. https://doi.org/10.1016/j.oraloncology.2012.07.015CrossRefPubMed

29.

Fakhry C, Zhang Q, Nguyen-Tan F et al (2014) Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol. https://doi.org/10.1200/JCO.2014.55.1937CrossRefPubMedPubMedCentral

30.

Faraji F, Eisele DW, Fakhry C (2017) Emerging insights into recurrent and metastatic human papillomavirus-related oropharyngeal squamous cell carcinoma. Laryngoscope Investig Otolaryngol. https://doi.org/10.1002/lio2.37CrossRefPubMedPubMedCentral

31.

Martel M, Alemany L, Taberna M et al (2017) The role of HPV on the risk of second primary neoplasia in patients with oropharyngeal carcinoma. Oral Oncol 64:37–43. https://doi.org/10.1016/j.oraloncology.2016.11.011CrossRefPubMed

32.

IARC France (2007) Tobacco control: reversal of risk after. 11.

Titel: HPV status and therapeutic initial strategy impact on survival and oncologic outcomes: 5-year results from the multicentric prospective cohort of oropharyngeal cancers Papillophar
verfasst von: Dorian Culié
Alexandra Rousseau
Jean-Luc Pretet
Jean Lacau Saint Guily
Publikationsdatum: 18.10.2021
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Oto-Rhino-Laryngology / Ausgabe 6/2022
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-021-07117-5

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

HPV status and therapeutic initial strategy impact on survival and oncologic outcomes: 5-year results from the multicentric prospective cohort of oropharyngeal cancers Papillophar

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update HNO

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2022

Assessment of preoperative and postoperative cardiac function in children with adenotonsillar hypertrophy: a prospective cohort study

Impact of the COVID-19 pandemic on head and neck cancer diagnosis: data from a single referral center, South Tyrol, northern Italy

A novel MYH9 mutation related to non-syndromic delayed post-lingual sensorineural hearing loss

Effect of cisplatin chemotherapy on the inner ear function and serum prestin concentration

The role of Glut-1 and H+/K+-ATPase expression in hyperplasia of mice laryngeal epithelium induced by pepsin

Correction to: Pretreatment tumor sampling and prognostic factors in patients with soft-tissue sarcoma of the head and neck

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update HNO